NASDAQ:PACB Pacific Biosciences of California (PACB) Stock Price, News & Analysis $1.22 -0.03 (-2.40%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$1.23 +0.01 (+0.82%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Pacific Biosciences of California Stock (NASDAQ:PACB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PACB alerts:Sign Up Key Stats Today's Range$1.21▼$1.2950-Day Range$1.12▼$1.7452-Week Range$0.85▼$2.73Volume4.63 million shsAverage Volume6.39 million shsMarket Capitalization$378.93 millionP/E RatioN/ADividend YieldN/APrice Target$1.83Consensus RatingReduce Company Overview Pacific Biosciences of California, Inc. develops, manufactures and sells high-performance DNA sequencing systems for genetic and genomic analysis. The company’s proprietary single-molecule, real-time (SMRT) sequencing technology is designed to enable long-read sequencing, offering high accuracy for applications such as de novo genome assembly, transcriptome characterization and structural variation analysis. Pacific Biosciences markets a suite of instruments, including the Sequel and Sequel IIe systems, alongside reagents, consumables and data analysis software to support a range of life science research. Founded in 2004 and headquartered in Menlo Park, California, Pacific Biosciences has expanded its global reach by serving academic institutions, biotechnology and pharmaceutical companies, and government research centers across North America, Europe and Asia. The company has established a network of distribution and service partners to support instrument installation, training and ongoing technical support in key markets around the world. Over its history, Pacific Biosciences has focused on advancing long-read sequencing capabilities, achieving milestones such as its initial public offering in 2010 and the launch of successive instrument generations to enhance throughput and data quality. Its technology has been applied to studies ranging from microbial genome sequencing to complex human genome analysis, reflecting its versatility in both basic and translational research. Led by President and Chief Executive Officer Christian Henry, Pacific Biosciences continues to invest in research and development aimed at increasing the speed, accuracy and affordability of long-read sequencing. The company’s strategic initiatives include expanding its consumables business, enhancing software tools for data interpretation and forming collaborations to address emerging needs in genomics and precision medicine.AI Generated. May Contain Errors. Read More Pacific Biosciences of California Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks33rd Percentile Overall ScorePACB MarketRank™: Pacific Biosciences of California scored higher than 33% of companies evaluated by MarketBeat, and ranked 721st out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingReduce Consensus RatingPacific Biosciences of California has received a consensus rating of Reduce. The company's average rating score is 1.80, and is based on no strong buy ratings, 1 buy rating, 2 hold ratings, and 2 sell ratings.Upside PotentialPacific Biosciences of California has a consensus price target of $1.83, representing about 50.3% upside from its current price of $1.22.Amount of Analyst CoveragePacific Biosciences of California has only been the subject of 3 research reports in the past 90 days.Read more about Pacific Biosciences of California's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Pacific Biosciences of California are expected to grow in the coming year, from ($0.50) to ($0.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pacific Biosciences of California is -2.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pacific Biosciences of California is -2.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPacific Biosciences of California has a P/B Ratio of 122.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Pacific Biosciences of California's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.54% of the float of Pacific Biosciences of California has been sold short.Short Interest Ratio / Days to CoverPacific Biosciences of California has a short interest ratio ("days to cover") of 7.04.Change versus previous monthShort interest in Pacific Biosciences of California has recently increased by 1.57%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPacific Biosciences of California does not currently pay a dividend.Dividend GrowthPacific Biosciences of California does not have a long track record of dividend growth. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 3 news articles for Pacific Biosciences of California this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for PACB on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows2 people have added Pacific Biosciences of California to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Pacific Biosciences of California insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $33,190.00 in company stock.Percentage Held by Insiders2.50% of the stock of Pacific Biosciences of California is held by insiders.Percentage Held by InstitutionsPacific Biosciences of California has minimal institutional ownership at this time.Read more about Pacific Biosciences of California's insider trading history. Receive PACB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pacific Biosciences of California and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PACB Stock News HeadlinesPacBio to Participate in the Jefferies Global Healthcare ConferenceMay 21 at 4:05 PM | globenewswire.comFinancial Review: Pacific Biosciences of California (NASDAQ:PACB) and SiBone (NASDAQ:SIBN)May 21 at 3:49 AM | americanbankingnews.comPorter flew 3,300 miles to investigate this systemPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.May 24 at 1:00 AM | Porter & Company (Ad)Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision OncologyMay 19, 2026 | businesswire.comPacific Biosciences (PACB) Reports Q1 EPSMay 13, 2026 | insidermonkey.comHiFi Solves Sub-fertility Consortium in Asia Pacific Reports First Major Study Using HiFi Long-Read Sequencing to Investigate Unexplained Subfertility and Recurrent Pregnancy LossMay 11, 2026 | globenewswire.comPACB Q1 Deep Dive: Consumables Growth and Clinical Adoption Offset Instrument WeaknessMay 11, 2026 | theglobeandmail.comPacBio tumbles after narrowing full-year revenue guidanceMay 8, 2026 | seekingalpha.comSee More Headlines PACB Stock Analysis - Frequently Asked Questions How have PACB shares performed this year? Pacific Biosciences of California's stock was trading at $1.87 at the beginning of the year. Since then, PACB shares have decreased by 34.8% and is now trading at $1.22. How were Pacific Biosciences of California's earnings last quarter? Pacific Biosciences of California, Inc. (NASDAQ:PACB) released its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.05. The biotechnology company earned $37.18 million during the quarter, compared to analyst estimates of $39.94 million. Pacific Biosciences of California had a negative trailing twelve-month return on equity of 571.06% and a negative net margin of 80.35%. Read the conference call transcript. Does Pacific Biosciences of California have any subsidiaries? Pacific Biosciences of California subsidiaries include these companies: Circulomics, Omniome, PacBio Singapore PTE Limited, Pacific Biosciences Canada Limited, Pacific Biosciences Germany GmbH, Pacific Biosciences Japan GK, Pacific Biosciences (Shanghai) Co. Ltd., Pacific Biosciences UK Limited, and Pacific Biosciences International LLC. When did Pacific Biosciences of California IPO? Pacific Biosciences of California (PACB) raised $200 million in an initial public offering on Wednesday, October 27th 2010. The company issued 12,500,000 shares at $15.00-$17.00 per share. Who are Pacific Biosciences of California's major shareholders? Top institutional shareholders of Pacific Biosciences of California include Sumitomo Mitsui Trust Group Inc. (2.27%), Amova Asset Management Americas Inc. (2.27%), Renaissance Technologies LLC (0.80%) and Bank of America Corp DE (0.54%). Insiders that own company stock include Christian O Henry, Oene Mark Van, Jeff Eidel, Michele Farmer and Susan G Kim. View institutional ownership trends. How do I buy shares of Pacific Biosciences of California? Shares of PACB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pacific Biosciences of California own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pacific Biosciences of California investors own include Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Alphabet (GOOG). Company Calendar Last Earnings5/07/2026Today5/24/2026AGM 20266/03/2026Jefferies Global Healthcare Conference 20266/04/2026Status update6/18/2026Next Earnings (Estimated)8/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 2 weeks, PACB's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:PACB CIK1299130 Webwww.pacb.com Phone(650) 521-8000Fax302-636-5454Employees730Year Founded2004Price Target and Rating Average Price Target for Pacific Biosciences of California$1.83 High Price Target$2.00 Low Price Target$1.50 Potential Upside/Downside+50.3%Consensus RatingReduce Rating Score (0-4)1.80 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$546.38 million Net Margins-80.35% Pretax Margin-79.84% Return on Equity-571.06% Return on Assets-18.82% Debt Debt-to-Equity RatioN/A Current Ratio5.65 Quick Ratio4.87 Sales & Book Value Annual Sales$160.01 million Price / Sales2.37 Cash Flow$0.79 per share Price / Cash Flow1.55 Book Value$0.01 per share Price / Book122.00Miscellaneous Outstanding Shares310,600,000Free Float302,837,000Market Cap$378.93 million OptionableOptionable Beta2.40 Social Links 5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:PACB) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredThe worst mistake you can make with the SpaceX IPOThe $1.75 trillion SpaceX IPO is generating massive hype - but history shows retail investors who pile in on d...Weiss Ratings | SponsoredYour $29.97 book is free todayBill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacific Biosciences of California, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pacific Biosciences of California With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
